Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study

Area of Science:

• Cellular therapy
• Translational medicine
• Clinical development

Background:

• Significant growth in basic science and clinical trials for cell therapy.
• Discrepancy between research activity and commercially available cell therapy products.
• Hypothesized lack of clinical community engagement as a barrier to commercial success.

Purpose of the Study:

• Investigate clinician perspectives on barriers to cell therapy development and adoption.
• Identify key concerns hindering widespread clinical use of cell therapies.
• Inform strategies to improve the translation of cell therapy research into practice.

Main Methods:

• Pilot study involving surveys of clinicians across five medical specialties.
• Qualitative and quantitative data collection on perceived challenges.
• Analysis of clinician feedback regarding regulatory, economic, and efficacy factors.

Main Results:

• Key barriers identified by clinicians include cost-effectiveness, efficacy, reimbursement, and regulatory hurdles.
• Clinician input highlights a need for better alignment between research and clinical practice.
• Cost, efficacy, reimbursement, and regulation are significant concerns for cell therapy adoption.

Conclusions:

• Enhanced engagement with the clinical community is essential for advancing cell therapy.
• Future clinical trials must address clinician and regulator concerns to facilitate adoption.
• Overcoming identified barriers is critical for the commercial success and widespread use of cell therapies.